Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Inclusion Criteria: * relapsed/refractory disease after receiving one line of standard chemotherapy * history of classical Hodgkin's Lymphoma (HL) * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * at least one site of measurable nodal disease at baseline ≥ 1.5 cm * Absolute Neutrophils Count (ANC) ≥ 1.5 x 109/L; Platelets count ≥ 75 x 109/L Exclusion Criteria: * Diagnosis of Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) * prior radiation therapy ≤ 3 weeks prior to start of study treatment * any concurrent anti-cancer therapy * evidence of another malignancy not in remission or history of such a malignancy within the last 2 years. * aspartate aminotransferase (AST/SGOT) and/or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x upper limit of normal (ULN) or ≥ 5.0 x ULN if the transaminase elevation is due to disease involvement * known history of Human immunodeficiency virus (HIV)seropositivity * hepatitis B virus (HBV) or hepatitis B virus (HCV)active hepatitis